Int J Oncol. 2016 Feb 24. [Epub ahead of print]
The membrane complement regulatory protein CD59 promotes tumor growth and predicts poor prognosis in breast cancer.
Ouyang Q, Zhang L, Jiang Y, Ni X, Chen S, Ye F, Du Y, Huang L, Ding P, Wang N, Yang C, Huang T, Sun Y, Li S, Xia Y, Hu W, Luo R, Shao Z.
Department of Breast Surgery, The Third Hospital of Nanchang, China Jiangxi Province Key Laboratory for Breast Diseases, Nanchang, Jiangxi, P.R. China; Fudan University Cancer Institute, Shanghai Cancer Center, Shanghai, P.R. China; Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Shanghai Cancer Center, Fudan University, Shanghai, P.R. China; Department of General Surgery, Affiliated Union Hospital of Fujian Medical University, Union Clinical School, Fujian Medical University, Fujian, P.R. China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P.R. China; Department of Hand Surgery, Huashan Hospital, Fudan University, Shanghai, P.R. China; Department of Urology, Shanghai Tenth People's Hospital, Tongji University, Shanghai, P.R. China; Cancer Center, Traditional Chinese Medicine-Integrated Hospital, Southern Medical University, Guangzhou, Guangdong, P.R. China.
Breast cancer is the most prevalent type of cancer among women. CD59, a membrane complement regulatory protein, has been demonstrated to be overexpressed in most solid tumors, where it facilitates tumor cell escape from complement surveillance. However, the role of CD59 in breast cancer growth and clinical prognosis is not fully revealed. To investigate the role of CD59 in breast cancer growth and prognostic significance, we knocked down CD59 in a breast cancer cell line that is highly metastatic to the lungs, MDA-MB-231-HM. Cell growth was measured in vitro and in vivo using a xenograft model. In addition, clinical data on a cohort of 120 patients with or without lung metastasis was analyzed based on CD59 expression, which was detected by immunohistochemistry. Knockdown of CD59 significantly inhibited MDA-MB-231-HM cell growth both in vitro and in vivo. An analysis of clinical data on 120 patients revealed that patients with CD59 overexpression may have a worse prognosis. CD59 may therefore be a prognostic biomarker for poor outcome in breast cancer patients.
PMID: 26935178
DOI: 10.3892/ijo.2016.3408
联系客服
